- Home
- PINE vs ENTA Comparison
PINE vs ENTA Comparison
Compare PINE & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | ENTA |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.9M | 382.7M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | PINE | ENTA |
|---|---|---|
| Price | $21.21 | $13.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $20.10 | ★ $20.40 |
| AVG Volume (30 Days) | 189.6K | ★ 237.8K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ 0.06 | N/A |
| Revenue | $60,532,000.00 | ★ $102,814,000.00 |
| Revenue This Year | $18.63 | $7.76 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $340.75 | ★ N/A |
| Revenue Growth | 15.90 | ★ 16.48 |
| 52 Week Low | $13.10 | $6.45 |
| 52 Week High | $21.32 | $17.15 |
Technical Indicators
Market Signals| Indicator | PINE | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 44.09 |
| Support Level | $18.80 | $13.00 |
| Resistance Level | N/A | $13.97 |
| Average True Range (ATR) | 0.56 | 0.71 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 88.51 | 8.49 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.